305 related articles for article (PubMed ID: 29129847)
1. Effects of ketoconazole on cyclophosphamide metabolism: evaluation of CYP3A4 inhibition effect using the in vitro and in vivo models.
Yang L; Yan C; Zhang F; Jiang B; Gao S; Liang Y; Huang L; Chen W
Exp Anim; 2018 Feb; 67(1):71-82. PubMed ID: 29129847
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of CYP3A4 and CYP3A5 catalyzed metabolism of alprazolam and quinine by ketoconazole as racemate and four different enantiomers.
Allqvist A; Miura J; Bertilsson L; Mirghani RA
Eur J Clin Pharmacol; 2007 Feb; 63(2):173-9. PubMed ID: 17200836
[TBL] [Abstract][Full Text] [Related]
3. Drug-drug interactions between ketoconazole and berberine in rats: pharmacokinetic effects benefit pharmacodynamic synergism.
Zhou Y; He P; Liu A; Zhang L; Liu Y; Dai R
Phytother Res; 2012 May; 26(5):772-7. PubMed ID: 22114028
[TBL] [Abstract][Full Text] [Related]
4. Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole.
Chien JY; Lucksiri A; Ernest CS; Gorski JC; Wrighton SA; Hall SD
Drug Metab Dispos; 2006 Jul; 34(7):1208-19. PubMed ID: 16611859
[TBL] [Abstract][Full Text] [Related]
5. Time- and NADPH-Dependent Inhibition on CYP3A by Gomisin A and the Pharmacokinetic Interactions between Gomisin A and Cyclophosphamide in Rats.
Zhai J; Zhang F; Gao S; Chen L; Feng G; Yin J; Chen W
Molecules; 2017 Aug; 22(8):. PubMed ID: 28786954
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory effects of ketoconazole, cimetidine and erythromycin on hepatic CYP3A activities in cats.
Shah SS; Sasaki K; Hayashi Y; Motoyama S; Helmi AR; Khalil WF; Shimoda M
J Vet Med Sci; 2009 Sep; 71(9):1151-9. PubMed ID: 19801894
[TBL] [Abstract][Full Text] [Related]
7. Effect of multiple dosing of ketoconazole on pharmacokinetics of midazolam, a cytochrome P-450 3A substrate in beagle dogs.
Kuroha M; Azumano A; Kuze Y; Shimoda M; Kokue E
Drug Metab Dispos; 2002 Jan; 30(1):63-8. PubMed ID: 11744613
[TBL] [Abstract][Full Text] [Related]
8. The effect of ketoconazole on praziquantel pharmacokinetics and the role of CYP3A4 in the formation of X-OH-praziquantel and not 4-OH-praziquantel.
Nleya L; Thelingwani R; Li XQ; Cavallin E; Isin E; Nhachi C; Masimirembwa C
Eur J Clin Pharmacol; 2019 Aug; 75(8):1077-1087. PubMed ID: 31089768
[TBL] [Abstract][Full Text] [Related]
9. Enantioselectivity of inhibition of cytochrome P450 3A4 (CYP3A4) by ketoconazole: Testosterone and methadone as substrates.
Dilmaghanian S; Gerber JG; Filler SG; Sanchez A; Gal J
Chirality; 2004 Feb; 16(2):79-85. PubMed ID: 14712470
[TBL] [Abstract][Full Text] [Related]
10. Effects of triptolide on the pharmacokinetics of cyclophosphamide in rats: a possible role of cytochrome P3A4 inhibition.
Zhang XF; Liu J; Ye F; Ji SG; Zhang N; Cao RS; He L; Wu JC; Li XF
Chin J Integr Med; 2014 Jul; 20(7):534-9. PubMed ID: 24420925
[TBL] [Abstract][Full Text] [Related]
11. Effect of CYP3A5 expression on the inhibition of CYP3A-catalyzed drug metabolism: impact on modeling CYP3A-mediated drug-drug interactions.
Shirasaka Y; Chang SY; Grubb MF; Peng CC; Thummel KE; Isoherranen N; Rodrigues AD
Drug Metab Dispos; 2013 Aug; 41(8):1566-74. PubMed ID: 23723360
[TBL] [Abstract][Full Text] [Related]
12. A Physiologically-Based Pharmacokinetic Modeling Approach To Predict Drug-Drug Interactions of Sonidegib (LDE225) with Perpetrators of CYP3A in Cancer Patients.
Einolf HJ; Zhou J; Won C; Wang L; Rebello S
Drug Metab Dispos; 2017 Apr; 45(4):361-374. PubMed ID: 28122787
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory effects of continuous ingestion of Schisandrin A on CYP3A in the rat.
Li WL; Xin HW; Su MW
Basic Clin Pharmacol Toxicol; 2012 Feb; 110(2):187-92. PubMed ID: 21895978
[TBL] [Abstract][Full Text] [Related]
14. A single-center, open-label, one-sequence study of dalcetrapib coadministered with ketoconazole, and an in vitro study of the S-methyl metabolite of dalcetrapib.
Derks M; Fowler S; Kuhlmann O
Clin Ther; 2009 Mar; 31(3):586-99. PubMed ID: 19393849
[TBL] [Abstract][Full Text] [Related]
15. Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates.
Fenneteau F; Poulin P; Nekka F
J Pharm Sci; 2010 Jan; 99(1):486-514. PubMed ID: 19479982
[TBL] [Abstract][Full Text] [Related]
16. Schisandra chinensis extract decreases chloroacetaldehyde production in rats and attenuates cyclophosphamide toxicity in liver, kidney and brain.
Zhai J; Zhang F; Gao S; Chen L; Feng G; Yin J; Chen W
J Ethnopharmacol; 2018 Jan; 210():223-231. PubMed ID: 28821392
[TBL] [Abstract][Full Text] [Related]
17. Leveraging Physiologically Based Pharmacokinetic Modeling and Experimental Data to Guide Dosing Modification of CYP3A-Mediated Drug-Drug Interactions in the Pediatric Population.
Salerno SN; Carreño FO; Edginton AN; Cohen-Wolkowiez M; Gonzalez D
Drug Metab Dispos; 2021 Sep; 49(9):844-855. PubMed ID: 34154994
[TBL] [Abstract][Full Text] [Related]
18. Relative contributions of the major human CYP450 to the metabolism of icotinib and its implication in prediction of drug-drug interaction between icotinib and CYP3A4 inhibitors/inducers using physiologically based pharmacokinetic modeling.
Chen J; Liu D; Zheng X; Zhao Q; Jiang J; Hu P
Expert Opin Drug Metab Toxicol; 2015 Jun; 11(6):857-68. PubMed ID: 25850339
[TBL] [Abstract][Full Text] [Related]
19. Quantitative prediction of metabolic inhibition of midazolam by itraconazole and ketoconazole in rats: implication of concentrative uptake of inhibitors into liver.
Yamano K; Yamamoto K; Kotaki H; Sawada Y; Iga T
Drug Metab Dispos; 1999 Mar; 27(3):395-402. PubMed ID: 10064572
[TBL] [Abstract][Full Text] [Related]
20. Effects of CYP3A4 Inhibitors Ketoconazole and Verapamil and the CYP3A4 Inducer Rifampicin on the Pharmacokinetic Parameters of Fostamatinib: Results from In Vitro and Phase I Clinical Studies.
Martin P; Gillen M; Millson D; Oliver S; Brealey C; Grossbard EB; Baluom M; Lau D; Sweeny D; Mant T; Craven K
Drugs R D; 2016 Mar; 16(1):81-92. PubMed ID: 26739683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
